SCHEMBL2201704

SCHEMBL2201704

Cc1ccc(C(=O)NCCO)cc1C(=O)c1ccc(Nc2ccccc2NC(=O)CCC(=O)O)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 10/20 0.52
MAPK12 P53778 10/20 0.52
MAPK11 Q15759 10/20 0.52
MAPK14 Q16539 10/20 0.52
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.41
HDAC3 O15379 2/20 0.41
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK8 P45983 1/20 0.39
MAPK10 P53779 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201708 1.00 MAPK13 (0.52) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2200115 0.91 MAPK14 (0.57) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2196091 0.89 MAPK14 (0.64) MAPK13MAPK12MAPK11MAPK14POLB
SCHEMBL2198593 0.89 MAPK14 (0.67) MAPK13MAPK12MAPK11MAPK14POLB
SCHEMBL2196948 0.86 MAPK14 (0.72) MAPK13MAPK12MAPK11MAPK14POLB
SCHEMBL2200606 0.85 MAPK14 (0.70) MAPK13MAPK12MAPK11MAPK14LMNA
SCHEMBL2198471 0.85 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14POLB
SCHEMBL2198645 0.84 MAPK14 (0.66) MAPK13MAPK12MAPK11MAPK14HDAC3
SCHEMBL6095615 0.84 MAPK14 (0.72) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL6095607 0.84 MAPK14 (0.72) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1826310-B Novel aminobenzophenone compounds LEO PHARMA AS 2010-07-21 CN claimed
CN-1826310-A Novel aminobenzophenone compounds LEO PHARMA AS (DK) 2006-08-30 CN claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
CN-1826310-B Novel aminobenzophenone compounds LEO PHARMA AS 2010-07-21 CN disclosed
CN-1826310-A Novel aminobenzophenone compounds LEO PHARMA AS (DK) 2006-08-30 CN disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.